The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...
If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...
Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...
Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.
The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...
Johnson & Johnson announced the submission of two supplemental Biologics License Applications, sBLAs, to the U.S. Food and Drug ...
Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...
The companies’ icotrokinra, or JNJ-2113, significantly cleared skin compared to placebo in patients with moderate to severe ...
Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.
Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Dr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback